Lupus, an autoimmune disease, can affect any part of the human body and has a long history of high mortality rates throughout the U.S. and around the world.
Millions of people around the world have lupus, experiencing many life-threatening and serious health challenges because of inadequate treatments and poor resources.
To fight against lupus, many leading physicians have used therapies that are designed for other diseases. The scientists altered these regimens to decrease the rates of mortality connected to lupus.
There are many different kinds of lupus, including related cardiovascular disease, kidney disease (called LN or lupus nephritis) and similar complications. Together, all of these factors result in high risk of early death for lupus patients.
Because of these health factors, scientists rarely publish information about lupus mortality. Lupus deaths are typically attributed to the heart attacks, kidney failure, infections or strokes related to lupus. Unfortunately, the root cause of these health conditions make it challenging to detect the true cause of the person’s death.
Drug development for resolving lupus has faced many challenges. Trials for new medications must be tested against other potent therapies that patients have already experienced before they are allowed to begin. There has only been one therapy, Benlysta, that has been approved for certain kinds of lupus.
